Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
Dare Bioscience, Inc. (DARE) filed this Current Report on Form 8-K on April 17, 2026, regarding the closing of a previously announced Regulation A offering. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
The filing details the issuance of equity securities rather than standard operating financial metrics such as revenue or cash flow.
- Transaction Type: Closing of a Regulation A offering.
- Units Issued: 20,000 Investor Units.
- Offering Price: $5.00 per Investor Unit.
- Components per Unit: One share of Series A Convertible Preferred Stock and two warrants to purchase one share of common stock each.
- Total Securities Issued: 20,000 shares of Series A Preferred Stock and warrants to purchase up to 40,000 shares of common stock.
- Maximum Offering Size: Up to 4,854,000 Investor Units (this closing represents a partial fulfillment).
Material Changes
The material change reported is the increase in the company's capital structure through the issuance of 20,000 Investor Units. This transaction was conducted pursuant to an offering statement on Form 1-A qualified by the SEC on April 1, 2026.
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking guidance, management commentary on future operations, or a discussion of risks beyond the standard incorporation by reference to previous filings (specifically the Form 8-K filed on January 29, 2026) for details on conversion and exercise terms.
Key Facts for Investor Verification
- Verify the total proceeds raised from this specific closing (20,000 units at $5.00).
- Review the terms of conversion for the Series A Preferred Stock and exercise prices for the Investor Warrants as detailed in the January 29, 2026, Form 8-K.
- Confirm the remaining capacity of the Regulation A offering (up to 4,854,000 total units).
- Check for any subsequent filings regarding the use of proceeds from this offering.